



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

09/582,342

09/18/2000

Rudi Brands

01975.0025

8325

22852

7590

06/02/2011

FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER
LLP

901 NEW YORK AVENUE, NW
WASHINGTON, DC 20001-4413

EXAMINER

FORD, ALLISON M

ART UNIT

PAPER NUMBER

1653

MAIL DATE

DELIVERY MODE

06/02/2011

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

1 RECORD OF ORAL HEARING

2
3 U.S. PATENT AND TRADEMARK OFFICE

4
5
6 BEFORE THE BOARD OF PATENT APPEALS
7 AND INTERFERENCES

8
9
10 *Ex parte* RUDI BRANDS

11
12
13 Appeal No. 2010-000543
14 Application No. 09/582,342
15 Technology Center 1600

16
17
18 Oral Hearing Held: January 19, 2011

19
20
21 Before LORA GREEN, FRANCISCO C. PRATS and STEPHEN WALSH,
22 *Administrative Patent Judges.*

23
24 APPEARANCES:

25
26 ON BEHALF OF THE APPELLANT:

27
28 JENNIFER R. GUPTA, ESQUIRE
29 Finnegan, Henderson, Farabow, Garrett &
30 Dunner, LLP
31 901 New York Avenue, N.W.
32 Washington, D.C. 20001-4413
33 (202) 408-4000
34

35 The above-entitled matter came on for hearing on Wednesday, January 19,
36 2011 commencing at 9:40 a.m., at the U.S. Patent and Trademark Office,
37 600 Dulany Street, Alexandria, Virginia, before Dawn A. Brown, Notary
38 Public.
39

P R O C E E D I N G S

- - - - -

THE USHER: Calendar Number 46, Appeal Number 2010-000543.

Ms. Gupta.

JUDGE GREEN: If you have a card or you can spell your name into the record for the court reporter. We are familiar with the record and you have 20 minutes whenever you would like to begin.

MS. GUPTA: Would you also like me to state my name for the record?

JUDGE GREEN: Yes, please.

MS. GUPTA: My name is Jennifer Gupta. I'm here with Finnegan, Henderson. And today we'll be discussing Application Number 09/582,342. This application has quite a long prosecution history, but I think it is whittled down to one 103 rejection and that is over three references -- Griffiths, which is a handbook, and two Internet articles, one entitled "Friendship Cake/Bread History" and the other entitled "Amish Friendship Bread."

The Supreme Court in KSR recognized there is a number of rationales to support a conclusion of obviousness. However, none of those rationales support the Examiner's conclusion of obviousness in the present application. The Examiner primarily relies upon the teaching-suggestion-motivation rationale. And under this rationale, the Examiner must identify the teaching, suggestion or motivation to modify or combine the references as well as a reasonable expectation of success to meet the proposed modification. We don't believe the Examiner has met that burden here.

The primary reference, Griffiths, discloses protocols for scaling off the suspension in anchorage-dependent cells. Anchorage-dependent cells are not

1 homogeneously dividing. They are attached to microcarriers.
2 However, the secondary references, they're disclosing process of preparing
3 bread. And unlike the anchorage-dependent cells, they use yeast cells, and the
4 yeast cells used in preparing bread are homogeneously divided in dough.
5 You know, while modifications and variations to improve methods can be
6 imported across different fields of art, in the present case, there is no reason
7 that one of ordinary skill in the art would import the techniques used in
8 making bread even if cell cultures are employed for use in a method where the
9 production of a biological and especially given that the cell cultures used in
10 bread are different than the anchorage-dependent cells.

11 As I said, the yeast cells are homogeneously divided in dough and the
12 anchorage-dependent cells are not. And the art here teaches how to handle the
13 anchorage-dependent cells. Griffiths teaches protocols for scaling up in
14 anchorage-dependent cells and recognizes the difficulties in doing so.
15 Because of the difficulties which are homogeneity problems associated with
16 scaling up anchorage-dependent cells, Griffiths teaches that suspension
17 cultures, not anchorage-dependent cultures, are always the preferred culture
18 method.

19 And another prior art reference, Groner, also recognizes the difficulties
20 associated with the scaling of the anchorage-dependent scales. It talks about
21 the scaling-up method necessitates opening the individual cell culture vessel
22 several times and is very labor-intensive, and it also creates a danger of
23 increased contamination of the cell culture.

24 To address those problems, Groner converts the anchorage-dependent cell to
25 cells that are grown in suspension to enable a better scaling-up process. So

1 based on those teachings, one of ordinary skill in the art would be unlikely to
2 use a splitting process, such as the repeated discontinuous process that we're
3 claiming, when using anchorage-dependent cells for the production of
4 biological.

5 And since the art teaches how to handle the anchorage-dependent cells, it
6 seems unlikely that one of ordinary skill in the art would then look to yeast
7 cells rather than what the art teaches for the production of a biological.

8 JUDGE GREEN: But then how do you have cells that you're going to use for
9 scale-up for the next batch? I mean, don't you have to start -- are you going to
10 reengineer your cells every time?

11 MS. GUPTA: No. The process is they scale that particular volume. They
12 divide it. They take a first part, a majority of the cells for producing the
13 biological. They leave a small amount remaining, 10 to 20 percent
14 approximately, and that they use to reseed to create a new preproduction batch.
15 And so they are always regenerating cells with the remaining cells leftover. So
16 it creates a cell bank to continue to use.

17 JUDGE WALSH: As I understand the Examiner's view, the Examiner
18 interpreted Griffiths as showing how to grow up or scale up all the cells. And
19 there was a particular section of Griffiths that you and the Examiner seem to
20 disagree on significantly.

21 The Examiner pointed to the passage where Griffiths says at the point at which
22 you're basically ready to harvest the cells, it says the cells will detach and can
23 be harvested, diluted in fresh medium and serum and passaged on.

24 Now, the Examiner says the word passaged on would include the concept of
25 using some of those cells for production of a biological and using some of the

1 cells as the basis for your new expansion or new scale-up. And I understood
2 the Examiner to be saying this is a well-known concept and it is even used in
3 things like making bread where you don't throw out or use up all of your bread
4 because you then have nothing to work with as Judge Green's question was.
5 But then if Griffiths was actually instructing people use up all the cells you
6 have, then what? Do you have to start over and reengineer?

7 I think as I understand that question, that was what the Examiner is getting at,
8 more practical to take some of these cells and scale them up again. I
9 understood that to be the Examiner's view. And what is wrong with that?

10 MS. GUPTA: I think the Examiner is saying that splitting the cell culture is
11 sort of inherent in the passaging on in Griffiths. But it is my understanding
12 that passaging of cells as it is described in Griffiths involves transferring all
13 the existing cells from one vessel to another. It is not splitting.

14 JUDGE WALSH: Do you have any evidence? A single vessel to a single
15 other vessel?

16 MS. GUPTA: Correct. As you -- in sequence, you continue to do that and to
17 get larger cells. You know, one of ordinary skill in the art may interpret that
18 some cells are left behind in a previous vessel, but it is my understanding that
19 those cells that are left behind are not used as a seed for subsequent
20 preproduction batch. They're just discarded. They're not used.

21 JUDGE WALSH: First question: Do you have any evidence that your
22 impression is shared by people of skill in the art?

23 MS. GUPTA: I have spoken with the inventor.

24 JUDGE WALSH: Evidence in the record that we can review.

25 MS. GUPTA: Just based on what Griffiths teaches and what the other

1 references -- Griffiths and Groner teach about the scaling up of
2 anchorage-dependent cells.

3 JUDGE WALSH: Second question: Even if that is correct, why would it not
4 have been obvious to do what the Examiner said, split these and save some of
5 them to scale up again for your next batch?

6 MS. GUPTA: I think that goes to what Groner is talking about.

7 JUDGE WALSH: Where is Groner in the record?

8 MS. GUPTA: It is WO 97/37000. It is discussed in the --

9 JUDGE WALSH: Did you provide that in your Evidence Appendix?

10 MS. GUPTA: Yeah. We discuss it in the Appeal Brief and the Reply Brief.

11 JUDGE WALSH: Actually, the Evidence Appendix seems to indicate no
12 evidence.

13 MS. GUPTA: We don't have any declaration evidence. It is prior art that is of
14 record, and it recognizes the difficulties in the scaling up of
15 anchorage-dependent cells. So it is not merely a combination of these known
16 techniques, the only predictable results. You know, the results of combining
17 these techniques are not predictable.

18 And the art at the time recognizes the difficulties in the scaling up of
19 anchorage-dependent cells being, you know, labor intensive as well as the
20 danger of contamination of the cells. Because as you continue to culture them
21 and you have to open up the vessels multiple times, it increases the
22 microorganisms in the culture vessels.

23 And so the Applicants have discovered a way to do the splitting process where
24 they're using the remaining cells and scaling up, and that -- it ensures the
25 safety of the cell line and it guarantees less contamination because they're

1 using the cells that they have already cultured up and the remaining cells to use
2 as a seed for a later preproduction batch.

3 JUDGE GREEN: Is your argument that because in the prior art they have
4 already scaled up and they leave 20 percent behind to start their next batch that
5 you don't have to go through the scaling up again and that is why the art
6 teaches away from the claimed invention?

7 MS. GUPTA: I think the art teaches away from the claimed invention because
8 the prior art teaches -- based on the difficulties with scaling up the
9 anchorage-dependent cells, it teaches using suspension cells rather than the
10 anchorage-dependent cells which we're using.

11 And so you wouldn't use the anchorage -- you would take
12 anchorage-dependent cells and convert them to suspension cells, and that is
13 what Groner teaches rather than take the anchorage-dependent cells and split
14 them and use a later -- the remaining cells leftover for the seed.

15 JUDGE GREEN: Okay.

16 MS. GUPTA: And I think also the fact that the art already tells how to handle
17 the anchorage-dependent cells that you wouldn't look outside to these methods
18 of culturing yeast cells for bread when trying to devise a process of using
19 anchorage-dependent cells for preparing the biological.

20 JUDGE GREEN: I think we understand your case. Thank you very much.
21 (Whereupon, the proceedings at 9:51 a.m. were concluded.)

22

23

24

25

26